Welcome to NGC. Skip directly to: Search Box, Navigation, Content.

Resources > Guideline Archive > Withdrawn NGC Summaries

Withdrawn NGC Summaries

Use the index below to find guidelines (listed by guideline developer) that have been withdrawn from the NGC Web site. Select "All" to see a complete list of withdrawn NGC Guideline Summaries (organized alphabetically by guideline developer). For a list of guidelines that have been updated, go to Updated NGC Summaries.

Guideline summaries are removed from the NGC Web site because they no longer meet the NGC Inclusion Criteria with respect to date, or because the guideline developer has indicated that the clinical practice guideline upon which the summary is based is obsolete, should no longer be used, or has not yet been replaced with a new/revised guideline. Please refer to the guideline developer's Web site, where available, for more information.

Note to PC users: If you are not sure which developer you need, consider using the "Find" option under the Edit menu or select Control-F to search the complete list by keyword.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

The National Guideline Clearinghouse™ currently contains 1389 guidelines in the withdrawn archive.

Pediatric Bariatric Study Group

  1. Bariatric surgery for severely overweight adolescents: concerns and recommendations. (NGC-3845)
    • Inge TH, Krebs NF, Garcia VF, Skelton JA, Guice KS, Strauss RS, Albanese CT, Brandt ML, Hammer LD, Harmon CM, Kane TD, Klish WJ, Oldham KT, Rudolph CD, Helmrath MA, Donovan E, Daniels SR. Bariatric surgery for severely overweight adolescents: concerns and recommendations. Pediatrics 2004 Jul;114(1):217-23. [46 references] PubMed

Philadelphia Panel

  1. Philadelphia Panel evidence-based clinical practice guidelines on selected rehabilitation interventions for knee pain. (NGC-4015)
    • Philadelphia Panel. Philadelphia Panel evidence-based clinical practice guidelines on selected rehabilitation interventions for knee pain. Phys Ther 2001 Oct;81(10):1675-700. [98 references] PubMed

  2. Philadelphia Panel evidence-based clinical practice guidelines on selected rehabilitation interventions for low back pain. (NGC-4016)
    • Philadelphia Panel evidence-based clinical practice guidelines on selected rehabilitation interventions for low back pain. Phys Ther 2001 Oct;81(10):1641-74. [130 references] PubMed

  3. Philadelphia Panel evidence-based clinical practice guidelines on selected rehabilitation interventions for neck pain. (NGC-4017)
    • Philadelphia Panel evidence-based clinical practice guidelines on selected rehabilitation interventions for neck pain. Phys Ther 2001 Oct;81(10):1701-17. [85 references] PubMed

  4. Philadelphia Panel evidence-based clinical practice guidelines on selected rehabilitation interventions for shoulder pain. (NGC-4018)
    • Philadelphia Panel evidence-based clinical practice guidelines on selected rehabilitation interventions for shoulder pain. Phys Ther 2001 Oct;81(10):1719-30. [60 references] PubMed

PinnacleHealth

  1. Management of decision-making incapacity in nursing homes. (NGC-0459)
    • MacLean DS. Management of decision-making incapacity in nursing homes. Nurs Home Med 1996 Mar;4(3):78-92. [22 references]

For more information, please refer to the PinnacleHealth Web site.

Program in Evidence-based Care

  1. Accelerated radiotherapy for locally advanced squamous cell carcinoma of the head and neck. (NGC-2990)
    • Head and Neck Cancer Disease Site Group. Accelerated radiotherapy for locally advanced squamous cell carcinoma of the head and neck [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2002 Oct [online update]. 19 p. (Practice guideline; no. 5-6c). [26 references]

  2. Adjuvant chemotherapy following complete resection of soft tissue sarcoma in adults. (NGC-4288)
    • Figueredo A, Bramwell VH, Bell R, Davis AM, Charette ML, Sarcoma Disease Site Group. Adjuvant chemotherapy following complete resection of soft tissue sarcoma in adults [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2005 Feb [online update]. 23 p. (Practice guideline report; no. 11-2). [43 references]

  3. Adjuvant systemic therapy for node-negative breast cancer. (NGC-3346)
    • Breast Cancer Disease Site Group. Adjuvant systemic therapy for node-negative breast cancer [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2003 May 1 [online update]. 22 p. (Practice guideline report; no. 1-8). [79 references]

  4. Altered fractionation of radical radiation therapy in the management of unresectable non-small cell lung cancer. (NGC-2825)
    • Lung Cancer Disease Site Group. Yu E, Lochrin C, Dixon P, Ung YC, Gagliardi A, Evans WK. Altered fractionation of radical radiation therapy in the management of unresectable non-small cell lung cancer [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2002 Sep [online update]. 25 p. (Practice guideline; no. 7-12). [34 references]

  5. Baseline staging tests in primary breast cancer. (NGC-3345)
    • Breast Cancer Disease Site Group. Baseline staging tests in primary breast cancer [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2003 Apr 30 [online update]. 14 p. (Practice guideline report; no. 1-14). [33 references]

  6. Breast irradiation in women with early stage invasive breast cancer following breast conserving surgery. (NGC-2426)
    • Cancer Care Ontario Practice Guideline Initiative (CCOPGI). Breast irradiation in women with early stage invasive breast cancer following breast conserving surgery [full report]. Toronto (ON): CCOPGI; 2002 Jan [online update]. Various p. (Practice guideline report; no. 1-2). [61 references]

  7. Capecitabine in stage IV breast cancer. (NGC-3351)
    • Breast Cancer Disease Site Group. Tomiak E, Verma S, Trudeau M, Robinson P. Capecitabine in stage IV breast cancer [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2003 Nov 26 [online update]. 17 p. (Practice guideline report; no. 1-16). [31 references]

  8. Concomitant chemotherapy and radiotherapy in squamous cell head and neck cancer (excluding nasopharynx). (NGC-2215)
    • Browman GP, Hodson DI, Mackenzie RJ, Bestic N, Zuraw L, Cancer Care Ontario Practice Guidelines Initiative (CCOPGI). Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: a systematic review of the published literature with subgroup analysis. Head Neck 2001;23:579-89. [51 references]


    • Cancer Care Ontario Practice Guideline Initiative (CCOPGI). Concomitant chemotherapy and radiotherapy in squamous cell head and neck cancer (excluding nasopharynx) [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2000 Mar [online update]. Various p. (Practice guideline; no. 5-6a). [48 references]

  9. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. (NGC-3841)
    • Sarcoma Disease Site Group. Bramwell VH, Anderson D, Charette ML. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2004 Jul [online update]. 19 p. (Practice guideline report; no. 11-1). [27 references]

  10. Drug therapy for chronic myeloid leukemia. (NGC-2231)
    • Cancer Care Ontario Practice Guideline Initiative (CCOPGI). Drug therapy for chronic myeloid leukemia [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2000 Jul [online update]. Various p. (Practice guideline; no. 6-3). [4 references]


    • Cancer Care Ontario Practice Guidelines Initiative. Drug therapy for chronic myeloid leukemia. Curr Oncol 2000;7(4):229-41. [28 references]

  11. Epirubicin, as a single agent or in combination, for metastatic breast cancer. (NGC-3344)
    • Breast Cancer Disease Site Group, Systemic Treatment Disease Site Group. Findlay BP, Walker-Dilks C, Pritchard K. Epirubicin, as a single agent or in combination, for metastatic breast cancer [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2003 Apr 30 [online update]. 15 p. (Practice guideline report; no. 1-6). [21 references]

  12. Fludarabine in intermediate- and high-risk chronic lymphocytic leukemia. (NGC-2509)
    • Cancer Care Ontario Practice Guideline Initiative (CCOPGI). Fludarabine in intermediate-and high-risk chronic lymphocytic leukemia [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2002 Feb. Various p. (Practice guideline; no. 6-1). [45 references]

  13. Hyperfractionated radiotherapy for locally advanced squamous cell carcinoma of the head and neck. (NGC-2827)
    • Head and Neck Cancer Disease Site Group. Mackenzie RG, Hodson DI, Browman GP, Zuraw L. Hyperfractionated radiotherapy for locally advanced squamous cell carcinoma of the head and neck [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2003 Jan [online update]. 13 p. (Practice guideline report; no. 5-6b). [22 references]

  14. Maximal androgen blockade for the treatment of metastatic prostate cancer. (NGC-2933)
    • Genitourinary Cancer Disease Site Group. Maximal androgen blockade for the treatment of metastatic prostate cancer [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2003 Feb 5 [online update]. 26 p. (Practice guideline; no. 3-1). [73 references]

  15. Neoadjuvant or adjuvant therapy for resectable gastric cancer. (NGC-3089)
    • Gastrointestinal Cancer Disease Site Group. Earle CC, Maroun J, Zuraw L. Neoadjuvant or adjuvant therapy for resectable gastric cancer [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2003 May 21 [online update]. 21 p. (Practice guideline; no. 2-14). [79 references]

  16. Optimal therapy for patients diagnosed with multiple myeloma and the role of high-dose chemotherapy and stem cell support. (NGC-3539)
    • Hematology Disease Site Group. Imrie K, Makarski J, Esmail R, Meyer R. Optimal therapy for patients diagnosed with multiple myeloma and the role of high-dose chemotherapy and stem cell support [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2003 Oct [online update]. 35 p. (Practice guideline report; no. 6-6). [106 references]

  17. Prophylactic cranial irradiation in small cell lung cancer. (NGC-3347)
    • Lung Cancer Disease Site Group. Kotalik J, Yu E, Markman BR, Evans WK. Prophylactic cranial irradiation in small cell lung cancer [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2003 Nov [online update]. 16 p. (Practice guideline report; no. 7-13-2). [15 references]

  18. Radiotherapy fractionation for the palliation of uncomplicated painful bone metastases. (NGC-2992)
    • Supportive Care Guidelines Group. Radiotherapy fractionation for the palliation of uncomplicated painful bone metastases [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2003 Mar. 22 p. (Practice guideline; no. 13-2). [48 references]

  19. Surgical management of early stage invasive breast cancer. (NGC-2932)
    • Breast Cancer Disease Site Group. Surgical management of early stage invasive breast cancer [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2003 Jan [online update]. 20 p. (Practice guideline; no. 1-1). [77 references]

  20. Surveillance programs for early stage non-seminomatous testicular cancer. (NGC-2220)
    • Cancer Care Ontario Guideline Practice Initiative (CCOPGI). Surveillance programs for early stage non-seminomatous testicular cancer [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2001 Jan [online update]. Various p. (Practice guideline; no. 3-5). [27 references]


    • Segal R, Lukka H, Klotz LH, Eady A, Bestic N, Johnston M, Genitourinary Cancer Disease Site Group, Cancer Care Ontario Practice Guidelines Initiative (CCOPGI). Surveillance programs for early stage non-seminomatous testicular cancer: a practice guideline. Can J Urol 2001 Feb;8(1):1184-92. [27 references] PubMed

  21. The role of aromatase inhibitors in the treatment of postmenopausal women with metastatic breast cancer. (NGC-3349)
    • Breast Cancer Disease Site Group. The role of aromatase inhibitors in the treatment of postmenopausal women with metastatic breast cancer [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2003 Oct [online update]. 22 p. (Practice guideline report; no. 1-5). [33 references]

  22. The role of colony-stimulating factor (CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. (NGC-3460)
    • Campbell C, Bramwell V, Charette M, Oliver T. Role of colony-stimulating factor in patients receiving myelosuppressive chemotherapy for treatment of cancer. Curr Oncol 2003;10(2):102-26.


    • Systemic Treatment Disease Site Group. Campbell C, Bramwell V, Charette M, Oliver T. The role of colony-stimulating factor (CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2003 Dec [online update]. 33 p. (Practice guideline report; no. 12-2). [76 references]

  23. The role of combination chemotherapy in the initial management of limited-stage small-cell lung cancer. (NGC-3467)
    • Lung Cancer Disease Site Group. Laurie SA, Logan D, Markman BR, Mackay JA, Evans WK. The role of combination chemotherapy in the initial management of limited-stage small-cell lung cancer [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2003 Dec [online update]. 51 p. (Practice guideline report; no. 7-13-1). [75 references]

  24. The role of neoadjuvant chemotherapy in locally advanced squamous cell carcinoma of the head and neck (SCCHN) (excluding nasopharynx). (NGC-2925)
    • Head and Neck Cancer Disease Site Group. Browman GP, Hodson DI, Newman T. The role of neoadjuvant chemotherapy in locally advanced squamous cell carcinoma of the head and neck (SCCHN) (excluding nasopharynx) [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2003 Feb [online update]. 10 p. (Practice guideline; no. 5-1). [36 references]

  25. The role of the taxanes in the management of metastatic breast cancer. (NGC-3052)
    • Breast Cancer Disease Site Group. Verma S, Trudeau M, Pritchard K, Oliver T. The role of the taxanes in the management of metastatic breast cancer [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2003 Apr 24. 31 p. (Practice guideline; no. 1-3). [116 references]

  26. The role of thoracic radiotherapy as an adjunct to standard chemotherapy in limited-stage small cell lung cancer. (NGC-2991)
    • Lung Cancer Diseases Site Group. The role of thoracic radiotherapy as an adjunct to standard chemotherapy in limited-stage small cell lung cancer [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2003 Jan [online update]. 20 p. (Practice guideline; no. 7-13-3). [30 references]

  27. The treatment of locally advanced pancreatic cancer. (NGC-3079)
    • Gastrointestinal Cancer Disease Site Group. Earle CC, Agboola O, Maroun J, Zuraw L. The treatment of locally advanced pancreatic cancer [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2003 May [online update]. 15 p. (Practice guideline; no. 2-7). [23 references]

  28. The use of bisphosphonates in men with hormone-refractory prostate cancer. (NGC-4110)
    • Genitourinary Cancer Disease Site Group. Berry S, Waldron T, Winquist E, Lukka H. The use of bisphosphonates in men with hormone-refractory prostate cancer [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2005 Jan 10. 34 p. (Practice guideline report; no. 3-14). [43 references]

  29. The use of chemotherapy and growth factors in older patients with newly diagnosed, advanced-stage, aggressive histology non-Hodgkin's lymphoma. (NGC-3261)
    • Hematology Disease Site Group. The use of chemotherapy and growth factors in older patients with newly diagnosed, advanced-stage, aggressive histology non-Hodgkin's lymphoma [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2003 Jun 25. 28 p. (Practice guideline; no. 6-7). [75 references]

  30. The use of conformal radiotherapy and the selection of radiation dose in T1 or T2 prostate cancer. (NGC-2687)
    • Cancer Care Ontario Practice Guideline Initiative (CCOPGI), Genitourinary Cancer Disease Site Group. Brundage M, Lukka H, Crook J, Warde P, Bauman G, Catton C, Markman BR, Charette M. The use of conformal radiotherapy and the selection of radiation dose in T1 or T2 prostate cancer [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2002 Oct. 23 p. (Practice guideline; no. 3-11). [81 references]

  31. Treatment with fludarabine for patients with follicular and other low grade Non-Hodgkin’s Lymphoma and Waldenstrom’s Macroglobulinemia. (NGC-3528)
    • Hematology Disease Site Group. MacEachern J, Chin-Yee I, Imrie K, Esmail R, Makarski J, Meyer RM. Treatment with fludarabine for patients with follicular and other low grade non-Hodgkin's lymphoma and Waldenstrom's macroglobulinemia [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2001 Nov. 18 p. (Practice guideline report; no. 6-2). [31 references]

  32. Use of 5-HT3 receptor antagonists in patients receiving moderately or highly emetogenic chemotherapy. (NGC-2972)
    • Systemic Treatment Disease Site Group. Use of 5-HT3 receptor antagonists in patients receiving moderately or highly emetogenic chemotherapy [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2003 Jan [online update]. 24 p. (Practice guideline; no. 12-3). [49 references]

  33. Use of adjuvant chemotherapy following cystectomy in patients with deep muscle-invasive transitional cell carcinoma of the bladder. (NGC-3263)
    • Genitourinary Disease Site Group. Segal R, Winquist E, Lukka H, Chin J, Brundage M, Markman B. Use of adjuvant chemotherapy following cystectomy in patients with deep muscle-invasive transitional cell carcinoma of the bladder [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2003 Jan 22. 18 p. (Practice guideline; no. 3-2-1). [19 references]

  34. Use of amifostine to ameliorate the toxic effects of chemotherapy in the treatment of cancer. (NGC-2929)
    • Systemic Treatment Disease Site Group. Vincent M, Bramwell V, Moran LA, Anderson D. Use of amifostine to ameliorate the toxic effects of chemotherapy in the treatment of cancer [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2003 Jan [online update]. 19 p. (Practice guideline; no. 12-6). [27 references]

  35. Use of chemotherapy in advanced unresectable or metastatic transitional cell carcinoma of the bladder or urothelium. (NGC-3258)
    • Genitourinary Disease Site Group. Use of chemotherapy in advanced unresectable or metastatic transitional cell carcinoma of the bladder or urothelium [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2002 Jun 19. 20 p. (Practice guideline; no. 3-12). [19 references]

  36. Use of gemcitabine in non-small cell lung cancer. (NGC-2828)
    • Lung Cancer Disease Site Group. Ellis P, Mackay JA, Evans WK. Use of gemcitabine in non-small cell lung cancer [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2002 Sep. 29 p. (Practice guideline; no. 7-8). [49 references]

  37. Use of irinotecan (Camptosar®, CPT-11) combined with 5-fluorouracil and leucovorin (5FU/LV) as first-line therapy for metastatic colorectal cancer. (NGC-2989)
    • Gastrointestinal Cancer Disease Site Group. Use of irinotecan (camptosar, CPT-11) combined with 5-fluorouracil and leucovorin (5FU/LV) as first-line therapy for metastatic colorectal cancer [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2003 Feb [online update]. 20 p. (Practice guideline; no. 2-16b). [17 references]

  38. Use of preoperative chemotherapy with or without postoperative radiotherapy in technically resectable stage IIIA non-small cell lung cancer. (NGC-2507)
    • Cancer Care Ontario Practice Guideline Initiative (CCOPGI). Use of preoperative chemotherapy with or without postoperative radiotherapy in technically resectable stage IIIA non-small cell lung cancer [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2002 Apr. Various p. (Practice guideline; no. 7-4).

  39. Use of strontium89 in patients with endocrine-refractory carcinoma of the prostate metastatic to bone. (NGC-2238)
    • Cancer Care Ontario Practice Guideline Initiative (CCOPGI). Use of strontium89 in patients with endocrine-refractory carcinoma of the prostate metastaic to bone [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2001 Oct [online update]. Various p. (Practice guideline report; no. 3-6). [14 references]

  40. Use of vinorelbine in non-small cell lung cancer. (NGC-2428)
    • Cancer Care Ontario Practice Guideline Initiative (CCOPGI). Use of Vinorelbine in non-small cell lung cancer [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2001 Aug [online update]. Various p. (Practice guideline; no. 7-5). [26 references]

For more information, please refer to the Program in Evidence-based Care Web site.




Search Help
Detailed Search
Frequent Searches

Resources

» Annotated Bibliographies
» Discussion List
» AHRQ Evidence Reports
» FAQ
» Glossary
» Guideline Resources
» Hospital Acquired Conditions
» New Features
» NLM Links
» Patient Resources
» PDA/Palm
» RSS Feeds
» Search Form